Agilius Biosciences partners with life science companies to accelerate medical countermeasures through government funding, commercialization support, and strategic policy engagement. Imagine having a fractional executive on your leadership team that knows all of the key players in the medical countermeasures world from the US Department of Defense, ASPR/BARDA, UK Ministry of Defence, Canadian Department of National Defence, NATO NSPA, COMEDS, and others. We help to navigate the intersection of science, policy, and government — from advising on how to secure non-dilutive funding to shepherding technologies through commercialization and into deployment. Our work spans the full development lifecycle, with particular depth in medical countermeasures, CBRN defense, and combat casualty care. Our team has direct experience successfully navigating the OTA process, obtaining funding from U.S. Government and allied agencies, and understands the complexities in the transition from CPE-CBRND to working with the Defense Logistics Agency (DLA) to get your product into deployment.